In the paper Printing Therapeutic Proteins in 3D using Nanoengineered Bioink to Control and Direct Cell Migration published by the team last May, they propose using the high surface area and charged characteristics of 2D nanosilicates (or nanoclays, nanoparticles of layered mineral silicates) to sequester and deliver biologically active therapeutics. Therapeutic proteins such as vascular endothelial growth factor (VEGF) and fibroblast growth factor (FGF) were incorporated into the bioink for in vitro testing, which was then used to fabricate a 3D structure using the HYREL System 30M 3D printer, a machine constructed with new custom extrusions, for easy mounting of various accessories, and three heads with full 200 x 200 x 200mm print volume, among other features.
The nanoengineered bioink loaded with therapeutic proteins is based on a nanoclay platform pioneered by Gaharwar that can be used for precise deposition of protein therapeutics, which Gaharwar developed as a new way to deliver treatment for cartilage regeneration and to eventually impact the treatment of osteoarthritis. This bioink formulation has unique shear-thinning properties with high printability and structural fidelity, that allow the material to be injected, quickly stop flowing and then cure to stay in place.
Charles Peak, senior author of the study and Assistant Instructional Professor at the Department of Biomedical Engineering at Texas A&M, said that “the prolonged delivery of the bioactive therapeutic could improve cell migration within 3D printed scaffolds and can help in rapid vascularization of scaffolds.”
While team leader, Gaharwar, said that the prolonged delivery of the therapeutic could also reduce overall costs by decreasing the therapeutic concentration as well as minimizing the negative side effects associated with supraphysiological doses (amounts greater than normally found in the body).
“Overall, this study provides proof of principle to print protein therapeutics in 3D that can be used to control and direct cell functions,” he suggested.
According to the published results, the shear-thinning bioink with the ability to sequester and release therapeutic proteins within 3D printed scaffolds is developed from a hydrolytically degradable polymer and 2D synthetic nanoparticles, with strong mechanical properties, swelling kinetics, and a degradation rate that can be modulated via the amount of PEG-DA and nanosilicates. The activity of released protein therapeutics from the 3D structure was verified via the migration of cells.
Supported by the National Institute of Biomedical Imaging and Bioengineering of the National Institutes of Health and the National Science Foundation, the research is in the midst of emerging bioprinting technologies for regenerative medicine and methods for rapidly fabricating
cell-containing constructs for designing new, healthy, functional tissues. According to Texas A&M, one of the major challenges in 3D bioprinting is the lack of control over cellular functions. Growth factors, which are a special class of proteins, can direct cellular fate and functions. However, these growth factors cannot be easily incorporated within a 3D-printed structure for a prolonged duration, which is why these developments at their Department of Biomedical Engineering lab are so relevant. And with so many papers on this subject, we will probably hear more about the team’s work with bioinks.[Images: Texas A&M, Wiley Online Library]
You May Also Like
CollPlant Biotechnologies Raise $5.5 Million
Regenerative medicine company CollPlant announced new fundraising of $5.5 million in convertible loans intended to support the advancement of their research projects in the fields of medical aesthetics and 3D...
3D Printing News Briefs: September 21, 2019
We’re talking about an event, some 3D printing education news, and racing applications in today’s 3D Printing News Briefs. Russia’s top 3D printing festival is returning for a second year,...
Investigating FDM 3D Printed Thermoplastic-Bonded Magnetic Composite Materials
While magnetic materials are pretty important when it comes to creating and implementing novel technologies, like 3D printing, it’s not easy to integrate or tune them in complicated designs, because...
Silicone 3D Printing Startup Spectroplast Completes CHF 1.5 Million Seed Round with AMV
Spectroplast AG, headquartered in Zurich, has just completed a CHF 1.5 million seed round with AM Ventures Holding GmbH (AMV), allowing them to move further ahead in silicone 3D printing....
View our broad assortment of in house and third party products.